SAMHSA: Q&A Session: Buprenorphine Induction for High Potency Synthetic Opioid Users

Wed, Apr 14 2021, 6 - 7pm

Q&A Session following a presentation on the use of injectable buprenophrine for the treatment of Opioid Use Disorder (OUD) in patients using Highly Potent Synthetic Opioids (HPSO). Attendees will be gain understanding of the pharmacology of HPSO, understand how current OUD pharmacotherapy interacts with HPSOs, and potential treatment options including long-acting injectable buprenorphine.

At the conclusion of this activity participants should be able to:

  1. Review the data supporting the use of injectable extended-release buprenorphine treatment for opioid use disorder.
  2. Identify special risks that fentanyl use presents and the possible role of injectable extended release buprenorphine treatment.
  3. Discuss the role of extended-release injectable buprenorphine in the treatment of OUD patients using fentanyl.